Access Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Access Bio develops and manufactures rapid diagnostic test kits, portable devices that detect diseases or health conditions from a blood, urine, or saliva sample without sending it to a laboratory.
Its products serve the point-of-care testing market, meaning clinics, pharmacies, or field settings where a fast result is needed on the spot. The company draws on three core technologies, immunochemical diagnostics, biosensors, and molecular diagnostics, and its diagnostic reagents are regulated as pharmaceutical products under Korean manufacturing standards. It is listed on KOSDAQ, South Korea's tech-focused small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Access Bio in five facts
What does Access Bio do?
Access Bio develops and manufactures rapid diagnostic test kits, portable devices that detect diseases or health conditions from a blood, urine, or saliva sample without sending it to a laboratory.
Where is Access Bio listed and in which sector?
Access Bio (Korean name: 엑세스바이오) trades under KRX code 950130 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Access Bio?
Its market capitalisation was US$53.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Access Bio's latest annual revenue and operating profit?
For fiscal year 2025, Access Bio reported revenue of US$16.6K, an operating loss of US$33.6K and a net loss of US$44.1K, per its annual report on DART (data retrieved from DART on 2026-09-25). Revenue was down 73.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-25
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed
Access Bio disclosed a supply contract with The Procter & Gamble Manufacturing Company, worth US$3.74M, about 15.89% of its recent annual revenue, running through Oct 2027.
Supply contract · Oct 20 - [Amended] Decision to acquire shares/equity in another company
Access Bio updated the disclosed terms of an acquisition of RF Bio Co., Ltd., now worth US$38.7M.
M&A · Apr 15 · 3 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Access Bio reported consolidated results for FY2025: revenue of US$21.7M (−72.2% year on year), an operating loss of US$43.9M and a net loss of US$57.6M.
Earnings · Feb 24